About the Company
Incyte Corp is a Wilmington, Delaware based biopharmaceutical company with an extensive global presence. With approximately 1,500 employees, the company has operations in the United States, Japan and Europe. With expertise in medicinal chemistry and biology, Incyte develops products, helmed by world-class scientists.
The company produces medicines under two franchises - Inflammation & Autoimmunity and Oncology. However, it develops medicines for four therapeutic areas, namely Immunology, Oncology, Rheumatology and Dermatology. As of 2020, it has 19 molecular targets and 22 clinical candidates it is working upon. Some of its medicines are Jakafi, INCB00928, INCB86550, Pemigatinib, Iclusig, Pemazyre, Monjuvi, Tabrecta, Olumiant, etc. The molecules it is developing for its drugs include FGFR, JAK, ARG, GITR, LAG-3, PI3Kδ, PD-1/PD-L1, TIM-3, etc.
Between 2009 and 2020, Incyte has collaborated with ten companies, producing medicines like capmatinib20, Tabrecta, baricitinib17 and Olumiant. Few of the notable companies it has partnered with are Eli Lilly and Company, Agenus Inc., MacroGenics Inc., MorphoSys AG, Novartis International Pharmaceutical Ltd., Zai Lab, Ltd., Merus N.V., Innovent Biologics, Inc., ARIAD Pharmaceuticals, Inc. and Calithera Biosciences, Inc.
Incyte was formed in 2002 by a group of scientists, biologists and chemists who were working in immunology. As of 2020, it is an S&P 500 component as well as a NASDAQ 100 component. It trades in the NASDAQ stock exchange under the ticker symbol INCY. It holds the 953rd rank in the 2020 Fortune 1000 list of companies. In the same year, it made into the Forbes list of Global 2000 companies. In 2018, it was the 7th most innovative company in the world, according to Forbes rankings.;
Organisation | Incyte Corporation |
Industry | Biotechnology |
HeadQuarters | Wilmington, DE |